ECSP17072987A - Compuestos nucleósidos 5-sustituidos - Google Patents
Compuestos nucleósidos 5-sustituidosInfo
- Publication number
- ECSP17072987A ECSP17072987A ECIEPI201772987A ECPI201772987A ECSP17072987A EC SP17072987 A ECSP17072987 A EC SP17072987A EC IEPI201772987 A ECIEPI201772987 A EC IEPI201772987A EC PI201772987 A ECPI201772987 A EC PI201772987A EC SP17072987 A ECSP17072987 A EC SP17072987A
- Authority
- EC
- Ecuador
- Prior art keywords
- cancer
- compounds
- substituted nucleoside
- nucleoside compounds
- cholangiocarcinoma
- Prior art date
Links
- -1 NUCLEOSIDE COMPOUNDS Chemical class 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a compuestos nucleósidos 5'-sustituidos novedosos, composiciones farmacéuticas que comprenden los compuestos, y métodos de utilización de los compuestos para tratar el cáncer, más particularmente para el tratamiento del cáncer, en particular los glioblastomas, melanoma, sarcomas, cáncer gástrico, cáncer de páncreas , colangiocarcinoma, cáncer de vejiga, cáncer de mama, cáncer de pulmón de células no pequeñas, leucemias, incluyendo leucemia mieloide aguda y los linfomas .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382225 | 2015-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17072987A true ECSP17072987A (es) | 2018-02-28 |
Family
ID=53177322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201772987A ECSP17072987A (es) | 2015-05-04 | 2017-11-01 | Compuestos nucleósidos 5-sustituidos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9840532B2 (es) |
| EP (1) | EP3292128A1 (es) |
| JP (2) | JP6181889B1 (es) |
| KR (1) | KR20170132871A (es) |
| CN (1) | CN107580602A (es) |
| AR (1) | AR104326A1 (es) |
| AU (1) | AU2016258485A1 (es) |
| BR (1) | BR112017020336A2 (es) |
| CA (1) | CA2981097A1 (es) |
| CL (1) | CL2017002637A1 (es) |
| CO (1) | CO2017010727A2 (es) |
| CR (1) | CR20170443A (es) |
| DO (1) | DOP2017000255A (es) |
| EA (1) | EA201792169A1 (es) |
| EC (1) | ECSP17072987A (es) |
| HK (1) | HK1244007A1 (es) |
| IL (1) | IL254409A0 (es) |
| MA (1) | MA42036A (es) |
| MX (1) | MX2017014001A (es) |
| PE (1) | PE20180231A1 (es) |
| PH (1) | PH12017502002A1 (es) |
| SG (1) | SG11201708345XA (es) |
| TN (1) | TN2017000459A1 (es) |
| TW (1) | TWI615400B (es) |
| WO (1) | WO2016178870A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031895B1 (ru) * | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| WO2018139181A1 (ja) * | 2017-01-27 | 2018-08-02 | 国立大学法人 宮崎大学 | 抗がん剤、抗がん剤のスクリーニング方法、がんに対する有効性判定キット及びがんに対する有効性判定方法 |
| WO2018152548A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| MA49840A (fr) * | 2017-08-09 | 2020-06-17 | Prelude Therapeutics Inc | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| EP3700906A1 (en) | 2017-10-26 | 2020-09-02 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| CR20200263A (es) | 2017-12-13 | 2020-07-26 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
| CA3092357A1 (en) | 2018-03-14 | 2019-09-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| WO2020206299A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| CR20220010A (es) | 2019-06-10 | 2022-05-13 | Lupin Ltd | Inhibidores de prmt5 |
| CA3154566A1 (en) | 2019-09-18 | 2021-03-25 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| GEP20247638B (en) | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354094A1 (en) * | 1999-08-27 | 2003-12-29 | Icn Pharmaceuticals, Inc.Icn Pharmaceuticals, Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| WO2013009735A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2014100764A2 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| US10118918B2 (en) | 2012-12-21 | 2018-11-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9365555B2 (en) * | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| EA031895B1 (ru) * | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
-
2016
- 2016-04-20 AR ARP160101081A patent/AR104326A1/es unknown
- 2016-04-22 TW TW105112724A patent/TWI615400B/zh not_active IP Right Cessation
- 2016-04-27 AU AU2016258485A patent/AU2016258485A1/en not_active Abandoned
- 2016-04-27 PE PE2017002330A patent/PE20180231A1/es not_active Application Discontinuation
- 2016-04-27 JP JP2016575652A patent/JP6181889B1/ja not_active Expired - Fee Related
- 2016-04-27 CN CN201680025080.3A patent/CN107580602A/zh active Pending
- 2016-04-27 HK HK18103599.9A patent/HK1244007A1/zh unknown
- 2016-04-27 SG SG11201708345XA patent/SG11201708345XA/en unknown
- 2016-04-27 BR BR112017020336-7A patent/BR112017020336A2/pt not_active Application Discontinuation
- 2016-04-27 WO PCT/US2016/029475 patent/WO2016178870A1/en not_active Ceased
- 2016-04-27 CR CR20170443A patent/CR20170443A/es unknown
- 2016-04-27 KR KR1020177031713A patent/KR20170132871A/ko not_active Withdrawn
- 2016-04-27 CA CA2981097A patent/CA2981097A1/en not_active Abandoned
- 2016-04-27 TN TNP/2017/000459A patent/TN2017000459A1/en unknown
- 2016-04-27 MA MA042036A patent/MA42036A/fr unknown
- 2016-04-27 EP EP16720676.2A patent/EP3292128A1/en not_active Withdrawn
- 2016-04-27 MX MX2017014001A patent/MX2017014001A/es unknown
- 2016-04-27 EA EA201792169A patent/EA201792169A1/ru unknown
- 2016-04-27 US US15/139,370 patent/US9840532B2/en not_active Expired - Fee Related
-
2017
- 2017-02-15 JP JP2017025494A patent/JP2017125029A/ja active Pending
- 2017-09-11 IL IL254409A patent/IL254409A0/en unknown
- 2017-10-17 CL CL2017002637A patent/CL2017002637A1/es unknown
- 2017-10-20 CO CONC2017/0010727A patent/CO2017010727A2/es unknown
- 2017-10-30 DO DO2017000255A patent/DOP2017000255A/es unknown
- 2017-11-01 EC ECIEPI201772987A patent/ECSP17072987A/es unknown
- 2017-11-03 PH PH12017502002A patent/PH12017502002A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016178870A1 (en) | 2016-11-10 |
| MX2017014001A (es) | 2018-03-16 |
| CA2981097A1 (en) | 2016-11-10 |
| TN2017000459A1 (en) | 2019-04-12 |
| MA42036A (fr) | 2018-03-14 |
| JP2017125029A (ja) | 2017-07-20 |
| US20160326208A1 (en) | 2016-11-10 |
| AR104326A1 (es) | 2017-07-12 |
| EP3292128A1 (en) | 2018-03-14 |
| TW201712022A (zh) | 2017-04-01 |
| JP6181889B1 (ja) | 2017-08-16 |
| CO2017010727A2 (es) | 2018-01-31 |
| US9840532B2 (en) | 2017-12-12 |
| JP2017525667A (ja) | 2017-09-07 |
| CN107580602A (zh) | 2018-01-12 |
| KR20170132871A (ko) | 2017-12-04 |
| IL254409A0 (en) | 2017-11-30 |
| SG11201708345XA (en) | 2017-11-29 |
| EA201792169A1 (ru) | 2018-03-30 |
| TWI615400B (zh) | 2018-02-21 |
| DOP2017000255A (es) | 2018-01-15 |
| PE20180231A1 (es) | 2018-01-31 |
| CL2017002637A1 (es) | 2018-04-20 |
| PH12017502002A1 (en) | 2018-03-26 |
| BR112017020336A2 (pt) | 2019-05-14 |
| AU2016258485A1 (en) | 2017-10-12 |
| CR20170443A (es) | 2017-11-07 |
| HK1244007A1 (zh) | 2018-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000255A (es) | Compuestos nucleósidos 5-sustituidos | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| JOP20200110A1 (ar) | متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات | |
| CO2017000359A2 (es) | Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa | |
| CL2015003491A1 (es) | Compuestos químicos. | |
| NZ716392A (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX2019015204A (es) | Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda. | |
| CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
| MX2017002824A (es) | Inhibidores demetilasa-1 especifica de lisina. | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| MX2017000179A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| ECSP17031525A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| CL2017001511A1 (es) | Derivados de piperidina como inhibidores de hdac1/2. | |
| ECSP17020172A (es) | Inhibidores de histona desmetilasa | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| MX2017001459A (es) | Sintesis de fosforamidatos. | |
| MX2018005305A (es) | Nuevos antiestrogenos heterociclicos. |